| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ELCPK | CTRPv2 | pan-cancer | AAC | 0.011 | 0.8 |
| mRNA | regorafenib | CTRPv2 | pan-cancer | AAC | 0.0081 | 0.8 |
| mRNA | PF-750 | CTRPv2 | pan-cancer | AAC | -0.0081 | 0.8 |
| mRNA | BRD-K63431240 | CTRPv2 | pan-cancer | AAC | -0.0074 | 0.8 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0068 | 0.8 |
| mRNA | AZD8055 | CTRPv2 | pan-cancer | AAC | -0.0072 | 0.8 |
| mRNA | cimetidine | CTRPv2 | pan-cancer | AAC | -0.015 | 0.9 |
| mRNA | GSK-J4 | CTRPv2 | pan-cancer | AAC | 0.025 | 0.9 |
| mRNA | BRD-K41597374 | CTRPv2 | pan-cancer | AAC | -0.0069 | 0.9 |
| mRNA | necrostatin-1 | CTRPv2 | pan-cancer | AAC | 0.0072 | 0.9 |